At Astra Generics, Research & Development (R&D) is at the core of our growth strategy. Our R&D division is focused on reverse engineering, formulation development, and scale-up of complex oncology molecules to meet the global demand for high-quality and affordable cancer therapies.
We integrate scientific expertise, advanced infrastructure, and regulatory know-how to accelerate development from laboratory to market, ensuring speed, compliance, and cost efficiency.
Oncology Generics Development
Expertise in developing targeted therapies, kinase inhibitors, and immuno-oncology generics.
Reverse engineering of high-value oncology molecules with patent expiries.
Formulation Development
Solid oral dosage forms (tablets, capsules) with complex release profiles.
Improved solubility and bioavailability technologies.
Development of fixed-dose combinations (FDCs) for enhanced treatment outcomes.
API Process Development
Cost-effective and scalable synthetic routes.
Continuous process optimization for yield and purity improvements.
Strong backward integration strategy to support long-term supply.
Analytical Development
State-of-the-art analytical labs for method development, validation, and stability studies.
Compliance with ICH, USFDA, EMA, and WHO guidelines.